Welcome to our dedicated page for CeriBell SEC filings (Ticker: CBLL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CeriBell, Inc. filings document the regulatory record of a medical technology company commercializing point-of-care EEG systems for neurological monitoring. Its Form 8-K reports include furnished financial results, FDA clearance events for the Clarity seizure-detection algorithm and other Ceribell System indications, and material agreements related to facility leases and headband supply arrangements.
The company’s proxy materials and governance filings cover annual meeting matters, board composition, committee assignments, director compensation arrangements, indemnification agreements, and related shareholder voting procedures. These disclosures provide formal records of Ceribell’s operating updates, governance structure, contractual obligations, and public-company reporting events.
CBLL filed Rule 144 notices reporting sales of Common Stock by an affiliate.
The filing lists completed sales by David J. Foehr on 02/23/2026 (569 shares, $11,263.07), 02/24/2026 (781 shares, $15,604.38), 03/03/2026 (4,560 shares, $81,168.00), and 05/21/2026 (987 shares, $17,761.95). The filing also records 862 shares associated with restricted stock vesting on 05/20/2026 tied to compensation.
CBLL: Rule 144 notice of proposed sale of Common Stock by an affiliate. The filing lists 987 shares of Common Stock associated with Restricted Stock Vesting and identifies Fidelity Brokerage Services LLC as the broker-dealer. The excerpt also reports three sales in the past three months: 569 shares for $11,263.07 on 02/23/2026, 781 shares for $15,604.38 on 02/24/2026, and 4,560 shares for $81,168.00 on 03/03/2026. The filing characterizes the 05/20/2026 entries as Compensation (restricted stock vesting).
CBLL filing a Form 144 reporting proposed sales of Common Stock by an affiliate. The notice lists multiple sale dates and quantities for a reporting person, including 705 shares on 02/23/2026, and several monthly sales (11,112; 11,112; 11,104) in 03/02/2026, 04/01/2026, and 05/01/2026 respectively. The filing also notes a Restricted Stock vesting on 05/20/2026 described as Compensation.
CBLL filed a Form 144 reporting a proposed sale of 6,030 shares of Common Stock. The filing lists the disposition method as tied to a Restricted Stock Vesting event on 05/20/2026 and shows multiple recent open-market dispositions by Xingjuan Chao in 02/2026–05/2026.
CBLL submitted a Form 144 notice for the sale of 1,378 shares of Common Stock associated with restricted stock that vested on 05/20/2026 as compensation. The filing lists Fidelity Brokerage Services LLC as broker and records a prior sale of 768 shares on 02/23/2026.
The issuer submitted a Form 144 notice relating to proposed disposition of Common Stock tied to a Restricted Stock Vesting event dated 05/20/2026. The filing shows a prior sale of 808 shares on 02/23/2026 by Scott E. Blumberg and references a brokerage account at Fidelity Brokerage Services LLC.
CeriBell, Inc. reports a Schedule 13G/A filing by The Global Value Investment Portfolio Management Pte Ltd and affiliated reporting persons.
The filing states beneficial ownership of 1,572,146 shares of Common Stock, equal to 4.2% of the class based on 37,859,680 shares outstanding as of March 31, 2026. The shares are held by u.life fund and none are held by GVIP Ventures SPC-SP3. The filing attributes shared voting and shared dispositive power of 1,572,146 shares to the reporting persons through The Global Value Investment Portfolio Management Pte Ltd and notes Caroline Kwong as Managing Director. Signature dates appear as May 14, 2026.
CeriBell, Inc. reported beneficial ownership information for Xingjuan Chao as of March 31, 2026. The filing shows 1,524,907 shares of Common Stock with sole voting power and shared voting power of 369,088, representing 4.9% of the class.
The filing states 37,859,520 shares outstanding as of March 31, 2026. It also discloses 826,328 shares issuable upon exercise of options exercisable within 60 days and 5,684 RSUs vesting within 60 days. The report is signed by Chao in her capacity as President and CEO.
CeriBell, Inc. reported strong top-line growth but wider losses for the quarter ended March 31, 2026. Revenue rose 29% year over year to $26.5 million, driven evenly by product sales of Wearables at $20.2 million and subscription revenue of $6.3 million. Gross margin remained high at 87%, reflecting the scalable nature of its model.
Operating expenses increased 36% to $43.9 million, mainly from higher headcount across functions and significant legal spending tied to an intellectual property enforcement matter, leading to a net loss of $19.7 million versus $12.8 million a year earlier, or ($0.52) per share. EBITDA was a loss of $20.5 million, and Adjusted EBITDA, which excludes stock-based compensation and specified IP litigation costs, was a loss of $11.2 million.
CeriBell ended the quarter with $141.2 million in cash, cash equivalents, and marketable securities and $20.0 million of term debt outstanding. Management believes this liquidity, together with expected cash from customers, can fund planned operations and capital needs for at least the next 12 months.
Ceribell, Inc. reported strong first quarter 2026 growth but wider losses. Total revenue was $26.5 million, up 29% from $20.5 million a year earlier, driven by both product and subscription growth, and gross margin remained high at 87%. The company ended the quarter with 680 active accounts and launched neonate and pediatric products after a successful pilot. Net loss widened to $19.7 million, or $0.52 per share, compared with a $12.8 million loss, as operating expenses rose to $43.9 million on commercial investments, added headcount, and IP litigation costs. Adjusted EBITDA loss was $11.2 million. Ceribell held $141.2 million in cash, cash equivalents, and marketable securities as of March 31, 2026, and raised its 2026 revenue guidance to $112–$116 million, implying approximately 26%–30% growth over the prior year.